Your race can have a significant impact on the healthcare you receive and even your risk of dying from cardiovascular disease. How can we as providers make a difference? The American Heart Association has declared structural racism as a cause of poor health and premature death from heart disease and stroke, recognizing that a person's…

Lifestyle Medicine 2021 (lmconference.org)

The complexity of heart failure management is the focus of PCNA's Virtual Heart Failure Summit, December 2, 2021. Heart failure is a chronic progressive disease affecting over 6.5 million Americans, and researchers expect the number to increase to eight million by the year 2030. Earn up to 2.25 continuing education contact hours when you join…

Join PCNA and the American Society for Preventive Cardiology on January 10, 2022 for a complimentary live webcast series. Individuals with HoFH are typically less responsive, or even unresponsive, to standard lipid-lowering therapies such as statins and PCSK9 inhibitors and may benefit from treatment modalities with other mechanisms of action. This curriculum is designed to…

Heart disease is the leading cause of death in America, accounting for about 1 in 4 fatalities each year. This sobering statistic has remained largely unchanged for decades within populations of color, particularly for Black Americans. To help uncover how we’ve arrived at this point and where to go from here, the Medical Alley Association…

The Heart Failure Society of America (HFSA) is hosting a virtual program of education and support for heart failure patients and caregivers. The program will give patients and caregivers the opportunity to participate in interactive educational sessions with the leading experts in the field. The objectives of the Heart Failure Patient and Caregiver Day are…

HoFH is a genetic disorder of lipid metabolism resulting in severely elevated LDL-C and early onset ASCVD and increased CV events and mortality. Individuals with HoFH are typically less responsive, or even unresponsive, to standard lipid-lowering therapies such as statins and PCSK9 inhibitors, and may benefit from treatment modalities with other mechanisms of action. This…

We're excited to be holding the 28th Annual Cardiovascular Nursing Symposium in person at the Flamingo Las Vegas Hotel. Virtual attendance is available as well through our webcast. The 2022 Cardiovascular Nursing Symposium will continue our tradition of combining clinically relevant content presented by world-renowned and regional experts with a vibrant atmosphere that allows you…

This half-day course will cover state-of-the-art topics on the management of patients at elevated risk of cardiovascular and cardiometabolic disease due to underlying systemic inflammation. This course is designed to provide an informative and practical guide towards the clinical management of cardiovascular disease in patients with systemic inflammation including those with recurrent pericarditis, dyslipidemia, and…